RBC Capital Markets’s $295 target on AXSM

AXSM Axsome Therapeutics Inc

$156 → $295 (+89%) by Oct 2027

Outperform · reiterates · said Oct 14, 2026 · 12-month default horizon

Open: judged on the close on Oct 14, 2027

The article this target came from

RBC Capital reiterates Axsome Therapeutics stock rating at Outperform

Investing.com · Oct 14, 2026

Investing.com - RBC Capital reiterated an Outperform stock rating on Axsome Therapeutics (NASDAQ:AXSM) with a $295.00 price target.

RBC Capital Markets’s track record → Axsome Therapeutics Inc →

A fact about what RBC Capital Markets published, as reported by Investing.com, not a recommendation from Dalsna Finance; RBC Capital Markets is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.